The addition of trastuzumab and pertuzumab to chemotherapy was associated with increased toxicity in patients with ...

结直肠癌（CRC）是全球范围内发病率和死亡率较高的恶性肿瘤之一。HER2 基因扩增在 CRC 中的发生率仅为 3%～5% [1] ，但与其预后密切相关，并已成为 ...

The approval is based on findings from a phase 3 study which demonstrated the drug’s superiority over chemotherapy.

Here are the most anticipated abstracts to keep an eye on going into the 2025 ASCO Gastrointestinal Cancers Symposium.

SOUTH SAN FRANCISCO - ALX Oncology Holdings Inc. (NASDAQ:ALXO), a clinical-stage biotechnology company with a market capitalization of approximately $95 million, reported positive outcomes from its ...

Adding evorpacept to treatment with trastuzumab, ramucirumab, and paclitaxel may improve outcomes in HER2-positive gastric/GEJ cancer.

US clinical-stage immuno-oncology biotech ALX Oncology Holdings released positive updated data from the ASPEN-06 Phase II ...